

# CRT Licensing Opportunity



## Novel Synthesis of Iduronate, a Heparan Sulphate Subunit

- Fully synthetic route to generate oligosaccharides
- Cost-effective scalable synthesis to yield clinical grade material in bulk
- Reactions run at ambient or near ambient temperatures
- Provision of stereopure L-Iduronate without chromatographic separation

ENABLING TECHNOLOGY

November 2010

### Background

Heparan sulfate and heparin play a central role in a large number of processes including anti-coagulation, angiogenesis, cell growth and migration. A new class of compounds can be envisaged that would either promote or inhibit the function of heparan sulfate/heparin by mimicking or competitively inhibiting the function of heparan sulfate/heparin.

### The Technology

The method of synthesis provides a cost-effective scalable route for the synthesis of iduronate. It is the first synthesis of iduronate to use relatively inexpensive reagents at room temperature and provides increased yields relative to standard methods of synthesis. The method has also been validated by combining the saccharide with other saccharides, confirming that longer oligosaccharides can be generated (currently synthesis of dodecassaccharides is possible).

### Potential Applications/ Application Areas

- Reagents for Research use
- Reagent for use in Diagnostic kits
- Synthesis of compounds for clinical use

### Intellectual Property

National/Regional applications deriving from the published patent WO06129075A1 have been filed in the United States of America, Europe and Japan. A further PCT application has been filed in 2009 (WO2009098449A1).

### Commercial Opportunity

CRT is currently seeking a Licensee for the method of synthesis technology.

**Contact:** *Martyn Bottomley*

*mbottomley@cancertechnology.com*

*Ph: +44 (0)203 469 6300*